EP3525798A4 - METHODS OF REDUCING PROTEINURY IN A HUMAN SUBJECT SUFFERING FROM IMMUNOGLOBULIN A NEPHROPATHY - Google Patents
METHODS OF REDUCING PROTEINURY IN A HUMAN SUBJECT SUFFERING FROM IMMUNOGLOBULIN A NEPHROPATHY Download PDFInfo
- Publication number
- EP3525798A4 EP3525798A4 EP17861108.3A EP17861108A EP3525798A4 EP 3525798 A4 EP3525798 A4 EP 3525798A4 EP 17861108 A EP17861108 A EP 17861108A EP 3525798 A4 EP3525798 A4 EP 3525798A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- nephropathy
- immunoglobulin
- methods
- human subject
- subject suffering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000010159 IgA glomerulonephritis Diseases 0.000 title 1
- 201000001474 proteinuria Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21104—Mannan-binding lectin-associated serine protease-2 (3.4.21.104)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Environmental Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Urology & Nephrology (AREA)
- Animal Husbandry (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662407979P | 2016-10-13 | 2016-10-13 | |
US15/399,524 US10736960B2 (en) | 2016-01-05 | 2017-01-05 | Methods for inhibiting fibrosis in a subject in need thereof |
US15/470,647 US20170253667A1 (en) | 2016-01-05 | 2017-03-27 | Methods for inhibiting fibrosis in a subject in need thereof |
US201762527926P | 2017-06-30 | 2017-06-30 | |
PCT/US2017/056386 WO2018071701A1 (en) | 2016-10-13 | 2017-10-12 | Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3525798A1 EP3525798A1 (en) | 2019-08-21 |
EP3525798A4 true EP3525798A4 (en) | 2020-07-08 |
Family
ID=61906454
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17861108.3A Pending EP3525798A4 (en) | 2016-10-13 | 2017-10-12 | METHODS OF REDUCING PROTEINURY IN A HUMAN SUBJECT SUFFERING FROM IMMUNOGLOBULIN A NEPHROPATHY |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP3525798A4 (pt) |
JP (1) | JP6893554B2 (pt) |
KR (1) | KR102348939B1 (pt) |
CN (2) | CN110177557A (pt) |
AU (1) | AU2017342428B2 (pt) |
BR (1) | BR112019007426A2 (pt) |
CA (2) | CA3210384A1 (pt) |
CL (2) | CL2019000909A1 (pt) |
GE (1) | GEP20247587B (pt) |
IL (1) | IL265981A (pt) |
JO (1) | JOP20190068A1 (pt) |
MA (1) | MA46541A (pt) |
MX (1) | MX2019004074A (pt) |
PH (1) | PH12019500711A1 (pt) |
SG (1) | SG11201902941UA (pt) |
UA (1) | UA126908C2 (pt) |
WO (1) | WO2018071701A1 (pt) |
ZA (1) | ZA201902933B (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111419860A (zh) * | 2020-03-19 | 2020-07-17 | 长春市儿童医院 | 一种肾小球分叶状肾病造模方法 |
CN115215937B (zh) * | 2021-04-15 | 2023-05-26 | 上海麦济生物技术有限公司 | 抗人masp-2抗体及其制备方法和应用 |
CN117016486B (zh) * | 2023-07-20 | 2024-05-14 | 上海澎立生技医药研究有限公司 | 一种IgA肾病合并膜性肾病的动物模型构建方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012151481A1 (en) * | 2011-05-04 | 2012-11-08 | Omeros Corporation | Compositions for inhibiting masp-2 dependent complement acitivation |
US20130266560A1 (en) * | 2011-04-08 | 2013-10-10 | University Of Leicester | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation |
WO2015058143A1 (en) * | 2013-10-17 | 2015-04-23 | Omeros Corporation | Methods for treating conditions associated with masp-2 dependent complement activation |
US20180153988A1 (en) * | 2016-08-31 | 2018-06-07 | Omeros Corporation | Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1625166B1 (en) * | 2003-05-12 | 2015-04-08 | Helion Biotech ApS | Antibodies to masp-2 |
US8840893B2 (en) * | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
US20140056873A1 (en) * | 2004-06-10 | 2014-02-27 | University Of Leicester | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation |
US7919094B2 (en) * | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
US7626730B2 (en) * | 2006-03-31 | 2009-12-01 | Eastman Kodak Company | Method of making a multilevel halftone screen |
WO2011047346A1 (en) * | 2009-10-16 | 2011-04-21 | Omeros Corporation | Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation |
WO2012100262A1 (en) * | 2011-01-21 | 2012-07-26 | Fibrogen, Inc. | Therapeutic method using anti - ctgf antibody |
KR101720562B1 (ko) * | 2011-04-08 | 2017-03-30 | 유니버시티 오브 레스터 | Masp-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법 |
CA2906096C (en) * | 2013-03-15 | 2022-03-15 | Omeros Corporation | Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same |
JP6682653B2 (ja) * | 2016-01-05 | 2020-04-15 | ユニバーシティー オブ レスター | 線維症の阻害を必要とする対象において線維症を阻害するための方法 |
-
2017
- 2017-06-16 JO JOP/2019/0068A patent/JOP20190068A1/ar unknown
- 2017-10-12 JP JP2019520140A patent/JP6893554B2/ja active Active
- 2017-10-12 SG SG11201902941UA patent/SG11201902941UA/en unknown
- 2017-10-12 WO PCT/US2017/056386 patent/WO2018071701A1/en unknown
- 2017-10-12 CN CN201780060710.5A patent/CN110177557A/zh active Pending
- 2017-10-12 CA CA3210384A patent/CA3210384A1/en active Pending
- 2017-10-12 MA MA046541A patent/MA46541A/fr unknown
- 2017-10-12 KR KR1020197012865A patent/KR102348939B1/ko active IP Right Grant
- 2017-10-12 MX MX2019004074A patent/MX2019004074A/es unknown
- 2017-10-12 GE GEAP201715070A patent/GEP20247587B/en unknown
- 2017-10-12 CA CA3039927A patent/CA3039927C/en active Active
- 2017-10-12 CN CN202310450575.2A patent/CN116726163A/zh active Pending
- 2017-10-12 UA UAA201904866A patent/UA126908C2/uk unknown
- 2017-10-12 EP EP17861108.3A patent/EP3525798A4/en active Pending
- 2017-10-12 BR BR112019007426A patent/BR112019007426A2/pt active Search and Examination
- 2017-10-12 AU AU2017342428A patent/AU2017342428B2/en active Active
-
2019
- 2019-04-01 PH PH12019500711A patent/PH12019500711A1/en unknown
- 2019-04-04 CL CL2019000909A patent/CL2019000909A1/es unknown
- 2019-04-11 IL IL265981A patent/IL265981A/en unknown
- 2019-05-10 ZA ZA2019/02933A patent/ZA201902933B/en unknown
- 2019-11-28 CL CL2019003485A patent/CL2019003485A1/es unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130266560A1 (en) * | 2011-04-08 | 2013-10-10 | University Of Leicester | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation |
WO2012151481A1 (en) * | 2011-05-04 | 2012-11-08 | Omeros Corporation | Compositions for inhibiting masp-2 dependent complement acitivation |
WO2015058143A1 (en) * | 2013-10-17 | 2015-04-23 | Omeros Corporation | Methods for treating conditions associated with masp-2 dependent complement activation |
US20180153988A1 (en) * | 2016-08-31 | 2018-06-07 | Omeros Corporation | Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods |
Also Published As
Publication number | Publication date |
---|---|
CA3210384A1 (en) | 2018-04-19 |
IL265981A (en) | 2019-06-30 |
CN110177557A (zh) | 2019-08-27 |
GEP20247587B (en) | 2024-01-25 |
WO2018071701A1 (en) | 2018-04-19 |
EP3525798A1 (en) | 2019-08-21 |
CA3039927C (en) | 2023-10-10 |
CN116726163A (zh) | 2023-09-12 |
KR102348939B1 (ko) | 2022-01-12 |
JP6893554B2 (ja) | 2021-06-23 |
MA46541A (fr) | 2019-08-21 |
AU2017342428A1 (en) | 2019-05-23 |
UA126908C2 (uk) | 2023-02-22 |
SG11201902941UA (en) | 2019-05-30 |
MX2019004074A (es) | 2019-06-10 |
PH12019500711A1 (en) | 2019-11-18 |
CA3039927A1 (en) | 2018-04-19 |
JP2019534271A (ja) | 2019-11-28 |
KR20190063475A (ko) | 2019-06-07 |
CL2019000909A1 (es) | 2019-06-14 |
CL2019003485A1 (es) | 2020-04-13 |
BR112019007426A2 (pt) | 2019-07-02 |
NZ753260A (en) | 2021-11-26 |
ZA201902933B (en) | 2023-05-31 |
JOP20190068A1 (ar) | 2019-04-01 |
AU2017342428B2 (en) | 2021-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3557339A4 (en) | LINKED ORDER PROCESS FOR INTERNET OF THINGS GATEWAY AND INTERNET OF THINGS GATEWAY | |
EP3430619A4 (en) | MODULAR SYSTEMS AND METHODS FOR SELECTIVELY DELIVERING CLOUD-BASED ASSISTANCE TECHNOLOGIES | |
EP3369002A4 (en) | METHOD AND DEVICE FOR FACILITATING THE PREDICTION OF CUSTOMER VISIONS | |
EP3183727A4 (en) | System and method for speech validation | |
EP3140763A4 (en) | Binding affinity prediction system and method | |
EP3164260A4 (en) | Systems and methods for fabricating joint members | |
EP3209803A4 (en) | Method and system for microbiome-derived diagnostics and therapeutics | |
EP3203964A4 (en) | System and method for adjusting a wheelchair seat | |
EP3312839A4 (en) | Device for assisting two-way conversation and method for assisting two-way conversation | |
EP3186025A4 (en) | Method and system for welding | |
EP3443094A4 (en) | PROCESS FOR REDUCING C9ORF72 EXPRESSION | |
EP3131498A4 (en) | Exoskeleton system for load carrying | |
EP3539130A4 (en) | DEVICES AND METHODS FOR STORAGE ORIENTATION | |
EP3104508A4 (en) | In-vehicle charger and surge-suppression method for in-vehicle charger | |
EP3162107A4 (en) | System and method for coordinated beamforming for overlapping basic service set in wlan | |
EP3417179B8 (de) | Verbindungsmittel und verfahren zum verbinden zweier bauteile | |
EP3143511A4 (en) | System and method for affinity-based network configuration | |
EP3162142A4 (en) | System and methods for enabling coordinated beamforming in overlapping basic service set in wlan | |
EP3280437A4 (en) | Egfr-directed car therapy for glioblastoma | |
EP3308223A4 (en) | MICRONET SYSTEM AND CONTROLLER | |
EP3142176A4 (en) | Fuel-cell system and method for controlling fuel-cell system | |
EP3179117A4 (en) | Movable device, movable seat, and method for manufacturing movable device | |
EP3161762A4 (en) | A method and system for enabling a payment | |
EP3167214A4 (en) | Curved shunt for solenoid curve shaping | |
EP3198966A4 (en) | System and method for link adaptation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20190503 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61K0031710500 Ipc: A61K0039395000 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20200605 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 39/00 20060101ALI20200529BHEP Ipc: A61K 39/395 20060101AFI20200529BHEP Ipc: A61K 45/06 20060101ALI20200529BHEP Ipc: A61P 13/12 20060101ALI20200529BHEP Ipc: C07K 16/40 20060101ALI20200529BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20230508 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20240112 |